Please note that the ASTRAL trial and its associated sub-studies closed to recruitment in October 2007.

  • At 1–3 months, 6 - 8 months, one year and annually thereafter until October 2017, fill in a simple form: creatinine, blood pressure, urinary protein (if available), adverse events, angiography (at one year – optional) and other medication.

Note: Patients in both treatment arms are to be seen at these times.